Hospital at HomeHOMeSALUTNCT07386275
Impact of the eSalut Program in Hospital-at-Home (HOMeSALUT)
A study testing eSalut program arm in people with Hospital at Home and Patients Admitted to Hospital at Home Unit, run by Germans Trias i Pujol Hospital at 1 site in Spain.
Trial summary
The objective of the study is to evaluate the impact caused by the use of the e-Salut Metro Nord App on the home hospitalization care process compared to the conventional model of care. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hospital at Home, Patients Admitted to Hospital at Home Unit
- What is being tested?
- eSalut program arm
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 202 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jan 2024to 15 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≥18 years old
- Admitted to HAD
- Ability to read Spanish/Catalan
- Minimum digital literacy
- Smartphone/tablet with Android or iOS
- Ability to answer calls and handle the App
- Patient or caregiver can manage the device
Who cannot join
- Patients living in nursing homes
- Voluntary withdrawal
- Complications requiring admission unrelated to study
- Loss of patient or caregiver
- No mobile device available
Trial locations and contacts
1 site in 1 country.
Spain1 site
Hospitalització a Domicili. Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916
About this study
Official title: Impact of Implementing Telemedicine in Home Hospitalization: e-Salut Project in Patients Admitted to the Home Hospitalization Unit of the Hospital Germans Trias i Pujol
The objective of the study is to evaluate the impact caused by the use of the e-Salut Metro Nord App on the home hospitalization care process compared to the conventional model of care.
A randomized clinical trial will be conducted with two groups: control group (patients using the conventional care model) and experimental group (patients using the app).
Read more
The study population includes patients admitted to the Home Hospitalization Unit (HAD) of the Hospital Universitari Germans Trias i Pujol who agree to participate between January 2024 and April 2025.
The independent variable is the use of the App. The dependent/outcome variables include: generated alerts, number of patient-initiated phone calls to professionals, App users who complete questionnaires, detected complications, unplanned in-person visits in HAD, unplanned phone visits in HAD, scheduled in-person nursing visits, scheduled medical visits, time elapsed between an alert and the professional's response, time for management and resolution of complications, unplanned visits generated by alerts, number of readmissions, patient/caregiver satisfaction, sex, age, functional assessment (Barthel Index), cognitive impairment assessment (Pfeiffer Test), anxiety and depression scales (HADS), patient activation measure (PAM-13), empowerment measure (CEPEC-47), therapeutic adherence test (ARMS-e), and health literacy (HLS-EU-Q16).
Read the detailed description
Several studies have shown that Home Hospitalization (HAD) improves clinical outcomes, reduces complications, lowers readmission rates, and generates substantial cost savings (15-17). In parallel, digital health technologies -including remote patient monitoring, mobile applications, and artificial intelligence- have demonstrated benefits in the early detection of clinical changes and in enhancing patient safety in home-based care settings (18-21).
It is within this context that the eSalut Program emerges, a digital platform developed to support active monitoring of patients admitted to HAD. The system integrates daily symptom reports, follow-up questionnaires, personalized educational exercises, automated clinical alert generation, and communication channels with the care team, with the aim of improving clinical decision-making and strengthening patient engagement by enabling active monitoring of their clinical status.
At the Hospital Universitari Germans Trias i Pujol (HUGTiP), the progressive deployment of the eSalut Program within the HAD service represents a unique opportunity to generate rigorous and valuable evidence for the healthcare system. The Program has been specifically designed to support acute clinical monitoring, integrating functionalities such as symptom tracking, automated alert generation, transmission of structured data, and protocol-based clinical response. These features may enhance early detection of clinical issues, reduce complications, and increase patient safety during home-based hospitalization.
In this context, the investigators pose the following research question: does the integration of the eSalut Program into Home Hospitalization (HAD) improve clinical outcomes and reduce unplanned events in patients with acute conditions? The hypothesis of the study is that the use of the eSalut Program will enable earlier detection of complications, a reduction in adverse incidents, and an overall improvement in clinical response.
The primary objective of this study is to assess the impact of the eSalut Program on patients admitted to HAD through a randomized clinical trial, analyzing clinical outcomes, generated alerts, complications, unplanned returns, and 30-day readmissions.
- Being tested
- eSalut program arm, Control arm
- Keywords
- Home Care Services, Hospital-Based, Mobile Applications, telemedicine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
eSalut program armOther
Also called eSalut
Patients admitted to home hospitalization care with the eSalut digital platform.
Control armOther
Also called Standard care
Patients admitted to home hospitalization receiving conventional care without the eSalut digital platform.
| Study group | Role | What they receive |
|---|---|---|
| eSalut Program arm | Experimental | Patients admitted to home hospitalization who will use the eSalut digital platform with symptoms monitoring, alerts and communication with the care team. Receives: Other: eSalut program arm |
| Control arm | Other | Patients admitted to home hospitalization receiving conventional care without the eSalut digital platform. Receives: Other: Control arm |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Hospital Readmission Within 30 Days After Discharge From Hospital-at-Home
Number of participants who experience at least one unplanned hospital readmission within 30 days after discharge from the Hospital-at-Home program.
Measured: 30 days post discharge
Secondary outcomes (10)
Length of Stay in Hospital-at-Home (Days)
Number of days each participant is admitted to the Hospital-at-Home (HAD) program, calculated from the day of admission to the day of discharge.
Measured: From admission (day 0) to discharge (up to 30 days)
Source of Clinical Alerts During Hospital-at-Home
Type of source that generates each clinical alert during the Hospital-at-Home (HaH) stay, categorized as: questionnaires, vital signs monitoring, patient-initiated phone calls, or analytical/laboratory results.
Measured: Up to 30 days after Hospital-at-Home admission
Number of Participants With Unplanned Return to Hospital During Hospital-at-Home
Number of participants who experience at least one unplanned return to the hospital while admitted to the Hospital-at-Home (HAD) program.
Measured: Up to 30 days after Hospital-at-Home admission
Number of Healthcare Visits by Modality During Hospital-at-Home
Number of healthcare visits received by participants during the Hospital-at-Home (HaH) stay, classified as: in-person medical visits, telephone medical visits, in-person nursing visits, and telephone nursing visits.
Measured: Up to 30 days after Hospital-at-Home admission
Patient Empowerment Score Assessed by the 47-item Patient Empowerment in Chronic Conditions Questionnaire (CEPEC-47)
The Patient Empowerment in Chronic Conditions Questionnaire (CEPEC-47) is a 47-item self-administered questionnaire that assesses patient empowerment across multiple domains, including autonomy, knowledge, and ability to participate in personal health care. Total scores range from 47 to 235, with higher scores indicating greater levels of patient empowerment.
Measured: Baseline and at discharge from Hospital-at-Home (mean 15 days)
Health Literacy Score Assessed by the 16-item European Health Literacy Survey Questionnaire (HLS-EU-Q16)
The 16-item European Health Literacy Survey Questionnaire (HLS-EU-Q16) is a self-administered instrument that assesses an individual's ability to access, understand, appraise, and apply health-related information. Total scores range from 0 to 16, with higher scores indicating better levels of health literacy. Scores can be categorized as inadequate (0-8), problematic (9-12), or sufficient (13-16) health literacy.
Measured: Baseline and at discharge from Hospital-at-Home (mean 15 days)
Patient Activation Score Assessed by the 13-item Patient Activation Measure (PAM-13)
The 13-item Patient Activation Measure (PAM-13) is a validated self-administered questionnaire that assesses an individual's knowledge, skills, and confidence for managing personal health. Total scores range from 0 to 100, with higher scores indicating higher levels of patient activation. Scores are categorized into four activation levels (Level 1: passive; Level 2: becoming aware; Level 3: taking action; Level 4: maintaining behaviors).
Measured: Baseline and at discharge from Hospital-at-Home (mean 15 days)
Medication Adherence Score Assessed by the Adherence to Refills and Medications Scale (ARMS-e)
The Adherence to Refills and Medications Scale (ARMS-e) is a self-administered questionnaire that evaluates adherence to medication-taking routines and prescription refill behaviors. Total scores range from 12 to 48, with lower scores indicating better medication adherence.
Measured: Baseline and at discharge from Hospital-at-Home (mean 15 days)
Anxiety and Depression Scores Assessed by the Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-administered questionnaire designed to screen for symptoms of anxiety and depression in medical patients. It includes two subscales: HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D), each ranging from 0 to 21, with higher scores indicating greater symptom severity.
Measured: Baseline and at discharge from Hospital-at-Home (mean 15 days)
Patient or Primary Caregiver Satisfaction Score With Hospital-at-Home Care
Patient or primary caregiver satisfaction is assessed using a structured satisfaction questionnaire developed for this study, measuring perceived quality of care, communication, safety, support, and overall experience during the Hospital-at-Home admission. Total scores range from 0 to 10, with higher scores indicating greater satisfaction.
Measured: One week after Hospital-at-Home discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2026
- Study start1 Jan 2024
- Primary completion30 Apr 2025
- Study completion15 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hospital at HomeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized clinical trial with two parallel groups.
- Masking
- None (open label)
- Enrolment
- 202 participants (actual)
Sponsor and investigators
- Lead sponsor
- Germans Trias i Pujol Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Meritxell Davins Riu, RN, PhD, Study director, Germans Trias i Pujol HospitalSandra Cabrera Jaime, RN, PhD, Study director, Institut Català d'Oncologia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07386275
- Sponsor's protocol ID
- PI-22-137
- Other IDs
- LT2309
- Acronym
- HOMeSALUT
- Status last verified
- Feb 2026
- First submitted
- 19 Jan 2026
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Implementing Telemedicine in Home Hospitalization: e-Salut Project in Patients Admitted to the Home Hospitalization Unit of the Hospital Germans Trias i Pujol
- ClinicalTrials.gov ID
- NCT07386275
- Acronym / sponsor ID
- HOMeSALUT / PI-22-137
- Keywords
- Home Care Services, Hospital-Based, Mobile Applications, telemedicine
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 202 participants (actual)
- Lead sponsor
- Germans Trias i Pujol HospitalUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 30 Apr 2025 (actual)
- Study completion
- 15 Aug 2025 (actual)
- First posted
- 4 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to evaluate the impact caused by the use of the e-Salut Metro Nord App on the home hospitalization care process compared to the conventional model of care.
A randomized clinical trial will be conducted with two groups: control group (patients using the conventional care model) and experimental group (patients using the app).
The study population includes patients admitted to the Home Hospitalization Unit (HAD) of the Hospital Universitari Germans Trias i Pujol who agree to participate between January 2024 and April 2025.
The independent variable is the use of the App. The dependent/outcome variables include: generated alerts, number of patient-initiated phone calls to professionals, App users who complete questionnaires, detected complications, unplanned in-person visits in HAD, unplanned phone visits in HAD, scheduled in-person nursing visits, scheduled medical visits, time elapsed between an alert and the professional's response, time for management and resolution of complications, unplanned visits generated by alerts, number of readmissions, patient/caregiver satisfaction, sex, age, functional assessment (Barthel Index), cognitive impairment assessment (Pfeiffer Test), anxiety and depression scales (HADS), patient activation measure (PAM-13), empowerment measure (CEPEC-47), therapeutic adherence test (ARMS-e), and health literacy (HLS-EU-Q16).
Detailed description
Several studies have shown that Home Hospitalization (HAD) improves clinical outcomes, reduces complications, lowers readmission rates, and generates substantial cost savings (15-17). In parallel, digital health technologies -including remote patient monitoring, mobile applications, and artificial intelligence- have demonstrated benefits in the early detection of clinical changes and in enhancing patient safety in home-based care settings (18-21).
It is within this context that the eSalut Program emerges, a digital platform developed to support active monitoring of patients admitted to HAD. The system integrates daily symptom reports, follow-up questionnaires, personalized educational exercises, automated clinical alert generation, and communication channels with the care team, with the aim of improving clinical decision-making and strengthening patient engagement by enabling active monitoring of their clinical status.
At the Hospital Universitari Germans Trias i Pujol (HUGTiP), the progressive deployment of the eSalut Program within the HAD service represents a unique opportunity to generate rigorous and valuable evidence for the healthcare system. The Program has been specifically designed to support acute clinical monitoring, integrating functionalities such as symptom tracking, automated alert generation, transmission of structured data, and protocol-based clinical response. These features may enhance early detection of clinical issues, reduce complications, and increase patient safety during home-based hospitalization.
In this context, the investigators pose the following research question: does the integration of the eSalut Program into Home Hospitalization (HAD) improve clinical outcomes and reduce unplanned events in patients with acute conditions? The hypothesis of the study is that the use of the eSalut Program will enable earlier detection of complications, a reduction in adverse incidents, and an overall improvement in clinical response.
The primary objective of this study is to assess the impact of the eSalut Program on patients admitted to HAD through a randomized clinical trial, analyzing clinical outcomes, generated alerts, complications, unplanned returns, and 30-day readmissions.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomized clinical trial with two parallel groups.
| Arm | Type | Receives |
|---|---|---|
| eSalut Program arm | Experimental | Other: eSalut program armPatients admitted to home hospitalization who will use the eSalut digital platform with symptoms monitoring, alerts and communication with the care team. |
| Control arm | Other | Other: Control armPatients admitted to home hospitalization receiving conventional care without the eSalut digital platform. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- ≥18 years old
- Admitted to HAD
- Ability to read Spanish/Catalan
- Minimum digital literacy
- Smartphone/tablet with Android or iOS
Key exclusion criteria (5 listed)
- Patients living in nursing homes
- Voluntary withdrawal
- Complications requiring admission unrelated to study
- Loss of patient or caregiver
- No mobile device available
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| eSalut program armAlso: eSalutPatients admitted to home hospitalization care with the eSalut digital platform. | Other | eSalut Program arm |
| Control armAlso: Standard carePatients admitted to home hospitalization receiving conventional care without the eSalut digital platform. | Other | Control arm |
Primary outcome
Number of Participants With Hospital Readmission Within 30 Days After Discharge From Hospital-at-Home
Time frame: 30 days post discharge
Number of participants who experience at least one unplanned hospital readmission within 30 days after discharge from the Hospital-at-Home program.
10 secondary outcomes
Length of Stay in Hospital-at-Home (Days)
Time frame: From admission (day 0) to discharge (up to 30 days)
Source of Clinical Alerts During Hospital-at-Home
Time frame: Up to 30 days after Hospital-at-Home admission
Number of Participants With Unplanned Return to Hospital During Hospital-at-Home
Time frame: Up to 30 days after Hospital-at-Home admission
Number of Healthcare Visits by Modality During Hospital-at-Home
Time frame: Up to 30 days after Hospital-at-Home admission
Patient Empowerment Score Assessed by the 47-item Patient Empowerment in Chronic Conditions Questionnaire (CEPEC-47)
Time frame: Baseline and at discharge from Hospital-at-Home (mean 15 days)
Health Literacy Score Assessed by the 16-item European Health Literacy Survey Questionnaire (HLS-EU-Q16)
Time frame: Baseline and at discharge from Hospital-at-Home (mean 15 days)
Patient Activation Score Assessed by the 13-item Patient Activation Measure (PAM-13)
Time frame: Baseline and at discharge from Hospital-at-Home (mean 15 days)
Medication Adherence Score Assessed by the Adherence to Refills and Medications Scale (ARMS-e)
Time frame: Baseline and at discharge from Hospital-at-Home (mean 15 days)
Anxiety and Depression Scores Assessed by the Hospital Anxiety and Depression Scale (HADS)
Time frame: Baseline and at discharge from Hospital-at-Home (mean 15 days)
Patient or Primary Caregiver Satisfaction Score With Hospital-at-Home Care
Time frame: One week after Hospital-at-Home discharge
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Hospital at Home
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Recruiting
Hospital-to-Home Rehabilitation Through Exercise and Cognitive Training
Acute Hospitalization
Not yet recruiting
Acute Hospital Care at Home for People Living With Dementia
Emergency Department Visit, Home Care Services
Recruiting
A Study of Hospital-at-Home for People Receiving Tarlatamab
Small-cell Lung Cancer, Small Cell Lung Carcinoma
Recruiting
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
Cirrhosis, End Stage Liver DIsease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Meritxell Davins Riu, RN, PhD study director
Germans Trias i Pujol Hospital
Sandra Cabrera Jaime, RN, PhD study director
Institut Català d'Oncologia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing eSalut program arm in people with Hospital at Home and Patients Admitted to Hospital at Home Unit, run by Germans Trias i Pujol Hospital at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Hospital Readmission Within 30 Days After Discharge From Hospital-at-Home (time frame: 30 days post discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.